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Purpose: We looked for any predictive value of change in 
primary tumor and metastatic lymph node volumes after 
induction chemotherapy (IC) on oncologic outcome in head 
and neck squamous cell carcinoma (HNSCC).
Methods: Nineteen patients with stage IVA/B HNSCC 
treated between 2004 and 2010 with at least one cycle of 
IC (docetaxel, cisplatin and 5-fluorouracil / TPF) and con-
comitant chemoradiotherapy (CRT) with cisplatin were ret-
rospectively analyzed. Volumes were calculated separately 
for primary tumor (Vtm), lymph node metastases (Vln) and 
their sum (Vsum) on computed tomography (CT) images be-
fore and after IC. The effect of volumetric changes on locore-
gional failure (LRF), distant metastasis (DM) and overall 
survival (OS) was assessed. P values <0.05 were considered 
as statistically significant.
Results: The median follow-up of surviving patients was 
25 months (range: 10.7-83.3). The median number of cy-
cles and duration of TPF was 3 (range: 1-4) and 44 days 
(range: 4-116), respectively. Empirical area under the 
curve (AUC) analyses for death, LRF and DM revealed 
optimal cut-off values of Vtm diminution (30.54%, AUC: 
87%) and Vsum decrease (35.45%, AUC: 64.55%) only 
for OS (p <0.05). Among those, a reduction in Vsum more 
than 35.4% between pre- and post-IC was significant-
ly correlated with better OS (100 vs 43% at 2 years, p 
<0.05).
Conclusion: Volumetric shrinkage of the tumor load after 
IC assessed with CT seems to predict OS. The assessment 
of volumetric shrinkage upon IC might be used to decide 
whether to offer patients alternative strategies like pallia-
tive/de-intensified treatments or more aggressive combined 
modalities after IC.
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Concomitant CRT is the standard therapeutic 
strategy for unresectable locoregionally advanced 
HNSCC [1]. When IC is administered, TPF chemo-
therapy has been shown to be superior to cisplatin 
and 5-fluorouracil only [2-4]. However, the debate 
whether to add IC prior to CRT is still ongoing. 
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The updated MACH-NC meta-analysis [1] and the 
recently presented meta-analysis by Budach et al. 
[5] did not show any superiority of IC followed 
by CRT over CRT alone. Recently published ran-
domized trials did not present consistent results 
favoring IC [6-9]. The only new positive trial by 
Ghi et al. [9] had a 2x2 factorial design and con-
comitant treatment arms contained either cis-
platin or cetuximab as systemic agent (full text 
not published), which makes it difficult to draw 
a sound conclusion. The multidisciplinary Head 
and Neck Tumor Board of the University Hospital 
of Bern selected only patients indicated for TPF 
IC before CRT in case of locoregionally advanced 
disease with inoperable tumor and/or nodal mass-
es which would also require extremely large tar-
get volumes and frequent adaptive re-planning in 
case of definitive CRT.
In HNSCC, the routinely used basic standard 
to estimate the outcome is the TNM stage. It takes 
the largest diameter and the anatomical local ex-
tent of disease, the number and size of involved 
lymph nodes and the presence or absence of dis-
tant metastases into account. On the other hand, 
it is also shown that the volumetric staging can be 
superior to TNM staging regarding prediction of 
outcome and TNM staging is not always correlat-
ed with the extent of disease burden [10-12]. 
Several studies were published demonstrat-
ing the predictive value of pre-treatment volume 
of primary tumor and/or involved lymph nodes 
on outcome in locoregionally advanced HNSCC 
treated with either surgery, CRT or radiation 
alone [13,14]. In addition, the ratio of volumetric 
change during CRT might also be predictive for 
local failure [15]. However, there is no consensus 
about any standard volumetric cut-off value to be 
used for volumetric staging.
In the past 10 years, some centers have begun 
to use IC routinely either as a standard protocol 
for locoregionally advanced HNSCC or just for se-
lected cases having very advanced  disease. Bisdas 
et al. [16] have associated tumor volume with CT 
prior to IC on 19 patients to disease-free survival 
(DFS).
The goal of this study was to look for any 
predictive value of volumetric change in primary 
tumor and metastatic lymph nodes due to IC on 
LRF, DM and OS in patients with locoregionally 
advanced HNSCC definitively treated with CRT af-
ter induction therapy. To our knowledge no article 
has yet been published regarding any predictive 
value of volumetric changes after IC on oncolog-
ical outcome.
Methods
Between 2004 and 2010, 389 cases diagnosed with 
oral, oropharyngeal, laryngeal and hypopharyngeal 
primary cancer were treated with definitive CRT. In 
this cohort, 40 patients with stage IVA/B (UICC/AJCC 
7th edition) biopsy-proven HNSCC treated with at least 
one cycle of IC and definitive CRT were retrospectively 
analyzed. The study was approved by the local Ethics 
Committee in accordance with the Helsinki Declara-
tion. Clinical staging was based on ENT-examination, 
panendoscopy and head and neck CT with or without 
18F-Fluorodeoxyglucose positron emission tomogra-
phy (18FDG-PET)-CT (thoracic CT in case of no 18FDG 
PET-CT). Twenty-one patients were excluded: 19 had 
missing digitalized imaging or data, 1 had a previously 
treated disease with lymph node recurrence, and an-
other one received 5 cycles of IC due to patient related 
reasons. 
IC consisted of docetaxel 75 mg/m2 as infusion 
over one hour followed by cisplatin 75 mg/m2 as infu-
sion over one hour on day 1, followed by fluorouracil 
1000 mg/m2 as continuous infusion for 4 days. Con-
comitant chemotherapy consisted of 2-3 cycles of cis-
platin 100 mg/m2 3-weekly. Cetuximab or carboplatin 
were used alternatively in patients in whom cisplatin 
was contraindicated. All patients were irradiated using 
intensity-modulated radiotherapy (IMRT) technique up 
to 72 Gy with 2 Gy per fraction, 5 times per week as we 
have described in detail in a previous article [17]. 
To compare the volumetric change in tumor bur-
den after IC, Vtm, Vln and Vsum before and after the 
completed course of IC were calculated as follows: in-
itial pre-IC images were imported into our radiother-
apy treatment planning system (Eclipse version 11.0, 
Varian, Palo Alto CA, USA). CT images performed be-
fore CRT for treatment planning were already stored in 
our system. The primary tumor and metastatic lymph 
nodes were contoured by the same radiation oncolo-
gist separately in each image set (Figure 1). Metastatic 
lymph nodes were defined as nodes with a diameter of 
≥10 mm in short axis (except for the jugulodigastric 
and retropharyngeal nodes in which  ≥15 mm and  ≥8 
mm were considered as malignant, respectively). At the 
end, all volumes were revised by a radiologist to avoid 
possible errors and improve accuracy. Volumes in cm3 
(mL) were calculated with the volume calculation algo-
rithm of the treatment planning software and recorded 
separately for Vtm, Vln and Vsum on the pre-IC and 
post-IC image sets for comparison.
Statistics
Descriptive statistics for patient characteristics 
were calculated. All time-to-event endpoints were 
calculated from the start of IC. Difference of volumes 
pre- to post-IC was assessed with paired Sign test. Ra-
tios of volumetric change after IC were calculated for 
Vtm, Vln and Vsum respectively. Receiver operating 
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characteristic (ROC) analyses were done for endpoints 
of LRF, DM and OS with an optimized sensitivity and 
specificity defined cut-off with the largest AUC. Surviv-
al curves for LRF, DM and OS were constructed with 
the Kaplan-Meier method and predictive value of cut-
off ratios regarding survival, LRF and DM were test-
ed with log-rank test. P values <0.05 were considered 
as statistically significant. SPSS software version 15 
(IBM, Chicago IL, USA) and JMP 9.0 (SAS Institute Inc. 
North Carolina, US) were used for statistical analyses.
Results
The median patient age was 60 years (range: 
41-73). Ten patients had their primary tumors 
Figure 1. Primary tumor (red) and metastatic lymph node (blue) structures pre-(A) and post-IC  (B) based on CT 
delination.
Figure 2. Change in volumes of primary tumor, involved lymph nodes and their sum. 
IC: Induction chemotherapy, Vtm: Volume of the primary tumor, Vln: Volume of metastatic lymph nodes, Vsum: Vtm 
+ Vln
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arising from the oropharynx, 6 from larynx and 3 
from hypopharynx.  The median number of cycles 
and duration of TPF was 3 (range: 1-4) and 44 days 
(range: 4-116), respectively. Five patients were ad-
ministered 1-2 cycles of TPF, 11 received 3 cycles 
and 3 received 4 cycles based on multidisciplinary 
tumor board decision. Six patients had interrup-
tions of CRT related to acute toxicity for a median 
of 2 days (range: 1-5). The median follow-up of 
surviving patients was 25 months (range: 10.7 – 
83.3). Statistically, none of those parameters were 
associated with survival.
Initial and post-IC mean volumes and related 
mean changes in percent are given in Table 1 and 
Figure 2. One patient did not have any lymph node 
metastases but only an extensive primary tumor.
Empirical AUC analyses for death, LRF and 
DM revealed significant optimal cut-off values 
of Vtm reduction (-30.54%, AUC: 87%) and Vsum 
reduction (-35.45%, AUC: 64.55%) only for OS (p 
<0.05). To predict the OS, the 35.45% decrease of 
Vsum was statistically significant in log-rank test 
(Figure 3). If the total radiological visible volume 
containing tumor and involved lymph node mass 
shrunk at least 35.45% after IC, OS at 2 years was 
significantly higher (100 vs 43%, p <0.05).
Discussion
Several studies and review articles have been 
published about the significant predictive value 
of primary tumor volume, metastatic lymph node 
volume and their sum on varying endpoints of 
outcome (local control, LRC, DM, OS and DFS) 
[13,14]. However, there is no consensus about the 
volume thresholds to be used. Only Studer et al. 
[12,18-20] extensively studied this issue and con-
sistently used a classification system divided by 
three thresholds.
Before the development and widespread use 
of software which enables 3D measurement of the 
volumes on images, cuboid and ellipsoid volume 
formulas (a×b×c and 1/6 xπ×a×b×c, respectively) 
were used to estimate the tumor and metastatic 
lymph node volumes [21-23]. Thanks to advanc-
es in imaging technologies some authors also 
included CT-based radiological indicators like 
lymphatic extracapsular spread [24], central nodal 
necrosis [21,25] or perfusion parameters [26] for 
predicting outcome and found significant results 
related to those factors. But in our study we did 
not include criteria other than simple volumetric 
parameters in standard contrast enhanced CT.
Almost all studies published on this subject 
evaluated the tumor burden before CRT or radi-
otherapy alone. Few articles about the value of 
tumor volume before IC were mostly focused on 
the correlation of volume with chemotherapy ef-
fects like tumor remission [27] or negative biopsy 
results [28]. Bisdas et al. [16] measured prima-
ry tumor volume with CT before IC and found a 
significant correlation with decreased DFS. Seol 
et al. [29] and Yu et al. [30] used metabolic pri-
mary tumor volume prior to IC measured with 
18FDG-PET-CT and found significant correlation 
Table 1. Measured volumes of primary tumor, metastatic lymph nodes and their sum
Measured volume Mean pre-IC volume in mL (range) Mean post-IC volume in mL (range)
Mean relative change
(%)
Vtm 45.3 (2.4-103.1) 25.4 (0-95.8) -43.6
Vln 58.1 (0-334.7) 22.7 (2.26-116.6) -39.0
Vsum 103.3 (13.81-392) 48.2 (4.8-148.1) -39.7
IC: Induction chemotherapy, Vtm: Volume of the primary tumor, Vln: Volume of metastatic lymph nodes, Vsum: Vtm + Vln
Figure 3. Overall survival stratified according Vsum re-
duction after IC. IC: Induction chemotherapy, Vsum: Sum 
of the primary tumor and metastatic lypmh node(s).
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with DFS. The methodologically most similar at-
tempt to our current study was from Yoon et al. 
[31] where they demonstrated the correlation of 
the percentage of maximum standardized uptake 
value (SUVmax) decrease regarding primary tu-
mor or metastatic lymph nodes after IC with the 
outcomes including clinical complete response, 
LRF and OS in a cohort of 21 patients. It was a 
study showing a relation between outcome and 
a quantitative ratio measurable from the start of 
IC to its end before CRT. However, the IC regi-
men was a non-standard protocol used in East 
Asia and the volumetric assessment was done 
with metabolic response and not with morpho-
logical changes. 
Detailed results and treatment related tox-
icities of this cohort is published previously [17]. 
To our knowledge, the present study is the first 
to evaluate the volumes before and after IC using 
proportional change in morphology, taking both 
primary tumor and metastatic lymph nodes into 
consideration. We evaluated the predictive value 
of total locoregional tumor shrinkage of at least 
-35% after IC on OS. It is also interesting to see, 
that our cut-off value is close to the partial re-
sponse threshold of -30%, defined by the widely 
accepted RECIST guideline [32] where the use of 
one-dimensional longest diameter but not a 3D 
volumetric assessment is required. On the other 
hand, it is interesting to observe a significant ef-
fect of volume change on OS without being able 
to find any optimal cut-off value for LRF or DM. 
The underlying reason for this lack of significance 
might be the limited sample size or another pa-
rameter we are not aware of.
The major limitation of our study besides its 
retrospective nature is the heterogeneity and the 
limited number of the patient cohort. In addition, 
the number of IC cycles varied due to toxicity. 
Moreover, patients responding to one or two cy-
cles could typically continue to respond during 
the next cycles. The cut-off value what we defined 
should be ‘fine-tuned’ with future studies having 
larger sample sizes. HNSCC, even with the same 
histopathology, follows different clinical courses 
regarding the primary tumor site. This is why it 
will be impossible to generate a uniform algo-
rithm for all subsites of the head and neck area. 
Therefore it is important to have cases with ho-
mogeneous disease sites or stratified large co-
horts in studies like this.
Today, administering TPF IC for locoregion-
ally  advanced HNSCC is justified and widely ac-
cepted, based on a high level of evidence only for 
larynx preservation purposes [33,34]. On the oth-
er hand, to choose IC for cases having extensive 
bulky disease remains to be an option.
By using these simple volumetric measure-
ments to calculate the volume reduction of the 
tumor mass after IC, it may be possible to assess 
patients who may be offered modalities combined 
with radical and morbid surgical options and clos-
er follow-up, or on the contrary, offer those poor 
responders less aggressive palliative approaches 
with modified radiation dose/fractionation/vol-
ume concepts (e.g. less total dose, split course, 
no elective irradiation), no or less toxic CRT. The 
CT-based method to calculate the volumes may be 
implemented in countries and healthcare settings 
where resources for other imaging techniques 
like 18FDG-PET-CT are limited. 
Conclusion
Primary tumor together with metastatic 
lymph node volume reduction after IC with a cut-
off value of at least -35.45% seems to be predic-
tive on OS in patients with stage IVA/B HNSCC. 
Shrinkage of the total locoregional tumor volume 
less than this cut-off value has an OS of 43% in 
comparison to a higher volume reduction with 
an OS of 100% at 2 years. However, these results 
need to be validated in future prospective stud-
ies with larger sample sizes to allow establishing 
their value as a measurement tool of stratification 
and allocation to treatment strategies.
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